Acute myeloid leukemia (AML) is a biologically heterogeneous group of related diseases in urgent need of better therapeutic options. Despite this heterogeneity, overexpression of the interleukin (IL)-3 receptor a-chain (IL-3 Ra/CD123) on both the blast and leukemic stem cell (LSC) populations is a common occurrence, a finding that has generated wide interest in devising new therapeutic approaches that target CD123 in AML patients. We report here the development of CSL362, a monoclonal antibody to CD123 that has been humanized, affinity-matured and Fc-engineered for increased affinity for human CD16 (FcgRIIIa). In vitro studies demonstrated that CSL362 potently induces antibody-dependent cell-mediated cytotoxicity of both AML blasts and CD34 þ CD38 À CD123 þ LSC by NK cells. Importantly, CSL362 was highly effective in vivo reducing leukemic cell growth in AML xenograft mouse models and potently depleting plasmacytoid dendritic cells and basophils in cynomolgus monkeys. Significantly, we demonstrated CSL362-dependent autologous depletion of AML blasts ex vivo, indicating that CSL362 enables the efficient killing of AML cells by the patient's own NK cells. These studies offer a new therapeutic option for AML patients with adequate NK-cell function and warrant the clinical development of CSL362 for the treatment of AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a biologically heterogeneous group of related diseases of the bone marrow (BM) and blood, characterized by uncontrolled proliferation of clonal, neoplastic myeloid precursor cells, and severe impairment or failure of normal hematopoiesis. Unfortunately, there have been few advances in the treatment of AML and, despite the fact that 70-80% of patients under 60 years of age will achieve complete remission, most will relapse and die from their disease. 1 The outlook for older patients is worse and so there is considerable interest in developing novel treatments. Any new treatments will need to take into account the considerable evidence indicating that AML is organized as a cellular hierarchy driven by leukemic stem cells (LSCs). [2] [3] [4] LSCs, by virtue of their quiescent nature, are resistant to many chemotherapeutics, and their survival in small numbers, coupled with their ability to self-renew and generate rapidly proliferating AML blasts has led to the proposal that they are responsible for reinitiation of disease. [5] [6] [7] CD123 (interleukin (IL)-3-Ra) is expressed in a variety of hematological malignancies including AML, myelodysplastic syndrome, B-cell acute lymphoblastic leukemia, Hodgkin's lymphoma, hairy cell leukemia, systemic mastocytosis, plasmacytoid dendritic cell (pDC) leukemia and chronic myeloid leukemia. [8] [9] [10] [11] [12] The majority of AML blasts express CD123 and it is also overexpressed on CD34 þ CD38 À LSCs compared with normal hematopoietic stem cells 13 and other normal tissues. This difference provides an opportunity to target the malignant cells selectively, and a CD123-specific antibody-based therapy could provide an attractive option for AML treatment, offering specificity and low toxicity compared with conventional chemotherapeutics.
We have shown previously that 7G3, a mouse monoclonal antibody (mAb), which prevents IL-3 binding to CD123, 14 was capable of eliminating human LSCs in a mouse model of human AML by a combination of mechanisms, including inhibition of homing and engagement of the innate immune system. 15 A human immunoglobulin (Ig)G1-chimeric version of 7G3 (CSL360) was evaluated in a phase 1 clinical study in patients with relapsed, refractory or high-risk AML. Encouragingly, this study demonstrated saturable targeting of CD123-positive AML cells, however, the lack of clear anti-leukemic activity, suggested that optimization of this antibody, particularly in its Fc region, was needed for the effective treatment of patients with advanced disease. 16 Fc-receptor-dependent effector mechanisms have been demonstrated to be important in the efficacy associated with some IgG1-based mAb therapies currently in clinical use (for example, Rituxan, Herceptin and Erbitux). Notably, better clinical outcomes have been observed in patients where innate effector cell populations express a CD16 (FcgRIIIa) allele that binds Ig Fc domains with an B10-fold higher affinity compared with the wildtype CD16 allele. [17] [18] [19] These observations have provided a level of clinical validation for strategies designed to enhance the recruitment of innate effector cells through the engineering of mAbs with increased affinity for CD16. Such strategies include the substitution of key residues within the antibody Fc domain that interact with CD16 20 and approaches that limit fucosylation on the Fc carbohydrate side chain. 21 mAbs incorporating these modifications have demonstrated enhanced in vitro killing of target cell populations and improved efficacy in various animal models of disease.
We show here the development of a second-generation anti-CD123 mAb, CSL362, that has been humanized, affinity-matured and engineered for increased affinity to CD16. This mAb potently induces antibody-dependent cell-mediated cytotoxicity (ADCC) of AML blasts and LSC in vitro and effectively depletes high CD123-expressing pDCs and basophils in non-human primates (NHPs). We suggest that CSL362 represents a new avenue for the treatment of AML that warrants further clinical investigation.
MATERIALS AND METHODS

Patient samples and cell lines
Peripheral blood (PB) and BM samples from AML patients were obtained after informed consent in accordance with protocols approved by the Human Research Ethics Committees of the Royal Melbourne Hospital and Royal Adelaide Hospital. PB mononuclear cells (PBMC) were separated by Ficoll (GE Healthcare, Uppsala, Sweden) density gradient centrifugation. CD34 þ CD38 À LSCs were sorted from AML samples as described previously. 15 PB from healthy donors was obtained from the Australian Red Cross Blood Service. NK cells were enriched using negative-selection kits from Miltenyi Biotec (Bergisch Gladbach, Germany). NK cells were depleted from PBMC preparations by fluorescence-activated cell sorting following labeling with anti-NKp46 (Beckman Coulter, Indianapolis, IN USA).
The human CD123-positive TF-1 erythroleukemia cell line was obtained from ATCC (CRL-2003) (Manassas, VA, USA). Lentivirus transduction was used to generate two TF-1 variant cell lines with differing levels of CD123 expression. The cells were maintained in RPMI/10% fetal calf serum supplemented with 2 ng/ml granulocyte-macrophage colony-stimulating factor in a humidified incubator at 37 1C with 5% CO 2 .
CD123 expression on cell lines and patient samples was determined by flow cytometry using anti-CD123 antibodies (clone 7G3-PE or 9F5-PE, BD Biosciences, Franklin Lakes, NJ, USA) and Quantibrite-PE beads (BD Biosciences).
Protein-binding assays
The extracellular domains of human CD123 (GenBank Accession: NP_002174), CD64 (NP_000557), CD32b (NP_003992) and CD16 (NP_001121065) were purified from transiently transfected Freestyle 293 suspension cells (Invitrogen, Carlsbad, CA, USA). Both the CD16-158V and CD16-158F polymorphic variants 26, 27 were produced. Kinetic and affinity analysis was performed at 37 1C using a Biacore 4000 surface plasmon resonance biosensor (GE Healthcare).
In vitro proliferation assay TF-1 cells were cultured in RPMI/10% fetal calf serum and 0.5 ng/ml IL-3 in the presence of increasing concentrations of CSL362 for 48 h at 37 1C before pulsing with 0.5 mCi 3 [H]-thymidine for 4 h and harvesting onto glass fiber filters. Radioactivity was quantitated by liquid scintillation counting.
In vitro ADCC assays
Target cells were incubated with test antibodies for 15 min before culturing with either NK cells or PBMC at various effector to target cell ratios (E:T) for 4-18 h at 37 1C in RPMI/5% fetal calf serum. Lactate dehydrogenase release was measured using either the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA) or the CytoTox-One reagent (Promega). Specific lysis was determined by normalizing the data to maximal (detergent) and minimal (effector cells alone) lysis.
Cell depletion assays
PBMCs from either healthy donors or AML patients were incubated with serial dilutions of CSL362 for 24 h in RPMI/10% fetal calf serum at 37 1C. 28 To evaluate autologous CSL362-mediated killing, AML cells from diagnosis were incubated with CSL362 (10 mg/ml), and PBMCs taken from the same patient at remission were used as effectors as described above. To demonstrate the effects of CSL362 on normal hematopoietic stem cells, BM cells from a healthy donor were incubated with purified autologous NK cells and CSL362 (10 mg/ml) as above and residual hematopoietic stem cell were determined by flow cytometry (
Murine xenotransplantation studies All mice were maintained using protocols and conditions approved by the Animal Care and Ethics Committee of the University of New South Wales. Transplantation of human cells into female nonobese diabetic/severe combined immunodeficiency (NOD.CB17-Prkdcscid/J) mice was performed as previously described. 15 Briefly, mice were exposed to sub-lethal irradiation (250 cGy) 1 day before intravenous injection of 2-10 Â 10 6 human AML cells. Engraftment levels were quantified by flow cytometry and expressed as the percentage of human CD45 þ (%hCD45 þ ) cells in the blood. Treatment was initiated when the %hCD45 þ cells in the blood reached 0.5%, corresponding to 4-9 weeks post engraftment, and was administered intraperitoneally at 300 mg/dose thrice weekly for 3-5 weeks. To generate event-free survival (EFS) curves, an event was defined when the %hCD45 þ reached 25% in the blood or when mice exhibited signs of leukemia-related morbidity. Efficacy was expressed as leukemia growth delay, defined as the difference in median event-free survival between the treated and control groups. Event-free survival curves were compared using the logrank test.
NHP study A cynomolgus NHP study was conducted at the Australian National Primate Facility in accordance with standard operating procedures following approval from the Institutional Animal Care and Use Committee. Naive monkeys were administered a single dose of CSL362 via intravenous infusion. PB was collected at various time points and analysis of basophils
þ and BDCA-2 þ ) and NK cells (CD159 þ , CD8 þ and CD16 þ ) performed by flow cytometry. Antibodies were sourced from BD Biosciences with the exception of BDCA2 (Miltenyi Biotec), IgE (KPL, Gaithersburg, MD, USA) and the anti-cyno CD123 antibody (HU01C2), which was generated in-house to a distinct epitope from CSL362.
RESULTS
Development of CSL362
CSL362 was developed from the murine anti-CD123 mAb 7G3 14 in a stepwise process of humanization, affinity maturation and Fc engineering. The humanization process 29 resulted in an B10-12-fold loss in affinity to CD123, which was restored by a ribosome display mutagenesis approach. 30 Variant clones were subsequently tested for both affinity for CD123 and IL-3 neutralization activity. The lead candidate, CSL362, was selected based on improved affinity for CD123 and restoration of biological potency in IL-3 neutralization assays.
To enhance cytotoxicity of the antibody, two amino-acid mutations (S239D and I332E) were introduced into the Fc region. 20 These changes significantly improve binding to CD16 (FcgRIIIa) on NK cells resulting in enhanced ADCC. 20 The characterization of CSL362 activity, including CD123 and FcR binding, anti-IL-3 activity, cytotoxicity and in vivo efficacy in animal models is detailed below.
CSL362 has increased affinity for CD16 and is a potent inhibitor of IL-3 Binding of CSL362 to CD123 was evaluated by surface plasmon resonance (Table 1) . CSL362 exhibited a modest, albeit significant, 1.6-fold improvement in affinity for CD123 compared with CSL360, a chimeric hIgG1-7G3 variant.
The affinity of CSL362 for CD16, CD64 (FcgR1) and CD32b/c (FcgRIIb/c) was also evaluated by surface plasmon resonance (Table 1 ). There was a substantial improvement in binding to both the low-affinity (158F) CD16 (157-fold) and high-affinity (158V) CD16 (129-fold) molecules compared with CSL360. A smaller, 38-fold improvement in binding to the inhibitory CD32b receptor was also observed. It has been proposed that optimal effector function is a result of a greater affinity to CD16 relative to CD32b. 20 The higher relative affinity of CSL362 to CD16 rather than CD32b (in contrast to CSL360) would be expected to translate to greater cytotoxic activity.
The ability of CSL362 to inhibit IL-3-mediated signaling and proliferation was examined in vitro using TF-1 cells. CSL362 neutralized IL-3 cytokine activity in a dose-dependent manner, comparable to CSL360 (Figure 1a ) and the parental 7G3 mAb (data not shown). At concentrations of IL-3 that corresponded to the EC 80 of the cytokine, inhibition of cell growth by at least 95% was routinely observed at 0.5 mg/ml (B3 nM) CSL362. In these assays both CSL362 and CSL360 have an estimated half-maximal inhibitory concentration of 0.01 mg/ml (B66 pM). These data demonstrate that CSL362 binds with high affinity to CD123 and is a potent inhibitor of IL-3 activity.
Enhanced CSL362-mediated ADCC of AML cells by NK cells To evaluate the functional consequences of increased affinity of CSL362 for CD16, we tested CSL362 for its ability to mediate ADCC.
CSL362 strongly mediated ADCC of TF-1 cells with a much greater effect than the non-Fc engineered anti-CD123 mAb CSL360 (Figure 1b) . Improved potency was reflected in both a shift in half maximal effective concentration toward a lower concentration and also in an increase in the maximal level of cell lysis. The half maximal effective concentration value of CSL362 in this assay was 5 ng/ml (33 pM) compared with 30 ng/ml (200 pM) for CSL360, a sixfold improvement. There was also a corresponding fivefold improvement in maximal lysis from 5-25%, over the 18-h period of this assay. The effect of CD123 expression levels on ADCC was also evaluated by using TF-1-CD123 cells that were engineered to express increasing levels of CD123, thus removing the variability in lysis caused by different cell backgrounds. Greater ADCC was observed as the levels of CD123 increased with maximal ADCC seen with cells expressing 12 000 CD123 molecules/cell (Figure 1c) . No significant increases in ADCC were seen in cells expressing 60 000 CD123 molecules/cell (Figure 1c) , indicating that once a certain level of CD123 density on the cell surface is reached optimal ADCC is achieved. CSL360 also demonstrated increased levels of cytotoxicity against cells expressing high levels of CD123, albeit significantly lower than that observed with CSL362 ( Supplementary Figure 1) . To determine which effector cell population elicits CSL362-mediated ADCC, TF-1 (low) cells were incubated with PBMC, purified NK cells or PBMC preparations where NK cells had been selectively depleted. The results of these experiments (Figure 1d ) clearly demonstrate that NK cells are the major effector population engaged by CSL362. We have confirmed this observation in separate studies, where we have examined the efficacy of CSL362-mediated ADCC using neutrophils, monocytes or macrophages as effector cells. In all cases, the lysis observed was minimal and no improvement owing to the Fc engineering was evident (Supplementary Figure 2) . Furthermore, minimal complement-mediated cytotoxicity was observed for CSL362 (Supplementary Figure 2) , confirming that the major mechanism of cell cytotoxicity for CSL362 is ADCC.
We next examined the ability of CSL362 to elicit ADCC of primary AML blasts (Figure 2a ) and LSC-enriched populations (Figure 2b ). For six different AML samples tested, CSL362 was shown to induce a mean maximal lysis of blasts of 31% (range 16-49%) compared with 4% (range 0-17%) for CSL360 (Table 2) .
Intriguingly, no strong correlation between the level of CD123 expression and maximum lysis was observed. Importantly, significant ADCC activity of CSL362 was demonstrated on CD34 þ 38 À LSC populations from four AML patients (mean lysis ¼ 77%, range 60-100%) ( Table 2 ). Maximal lysis of primary AML cells was routinely observed between 0.1 and 1.0 mg/ml (0.6-6 nM) of CSL362. To determine whether NK cells were limiting, AML cells were incubated with healthy donor NK cells at various E:T ratios. Residual CD34 þ cells and CD34 þ CD38 À LSCs were visualized by flow cytometry after 24 h (Figure 2c ). Higher NK:AML ratios resulted in greater depletion of target cells, particularly in the targeting of the LSC population from this patient, highlighting the importance of NK cells in the mechanism of action of CSL362.
CSL362 is highly efficacious in a mouse model of human AML In previous studies, we demonstrated that the efficacy of 7G3 (the parental mouse mAb) in nonobese diabetic/severe combined immunodeficiency animals was owing, at least in part, to the Fc region of the antibody and to residual NK cells in the mice. 15 We have used this model to evaluate the relative efficacy of CSL362 over a non-Fc-engineered anti-CD123 mAb in vivo, after demonstrating that CSL362 had increased affinity for the murine FcgRs receptors (data not shown).
CD123-positive AML xenografts were performed to compare the anti-tumor activity of CSL362 with a non-ADCC-enhanced anti-CD123 mAb (WT/CSL360). In these experiments, the tumor was allowed to establish before treatment with antibody was initiated. In four separate experiments, treatment with CSL362 resulted in a significant delay in tumor growth compared with an isotype control. This was in contrast to the non-ADCC-enhanced mAb, where there was no significant delay in tumor growth. In the three experiments where CSL362 was compared with CSL360/WT, a significant difference was also observed (Figure 3c ) with CSL362 being more efficacious in delaying tumor growth. An example of an AML treatment model with AML-5 is shown in Figure 3 . These data demonstrate that increasing affinity to FcgR's results in a corresponding improvement in anti-tumor activity in vivo.
Efficient depletion of basophils and pDCs in human blood ex vivo and in NHPs in vivo by CSL362
The ability of CSL362 to target CD123-positive cells in PB from normal donors was examined in whole-blood/PBMC depletion experiments, in which both FcgR-positive effector cells, including NK cells, monocytes and neutrophils and various potential targets including basophils, pDCs and monocytes were present. PB basophils and pDCs both express high levels of CD123 (B22 800 and B29 000 CD123 receptors/cell, respectively), whereas monocytes have relatively low expression (B360 receptors/cell each) (data not shown). CSL362 effectively depleted both basophils and pDCs in these assays (Figure 4a ), but the monocyte population remained largely unchanged. In addition, a clear activation of NK cells, demonstrated by the upregulation of the degranulation marker CD107a was seen following exposure to CSL362 (Figure 4b ).
To investigate the role of CSL362 in vivo, we chose the cynomolgus monkey as a relevant species for in vivo investigations based on a high degree of CD123 target sequence homology and expression with humans, demonstrated similarity in antibodybinding affinity to CD123 and FcgRs and comparable activity in cell-based assays.
To evaluate the ability of CSL362 to deplete circulating CD123-positive cells, 12 naive cynomolgus monkeys were administered a single dose of CSL362, and PB basophils and pDCs were measured at different times post dose. A rapid reduction (within 6 h) in both cell populations was observed at all dose levels (0.01-10 mg/kg). Recovery of these cells to close to baseline levels was observed 4 weeks post treatment (Figures 4c and d) . A transient reduction in PB NK cells coincident with the depletion of basophils and pDCs was also observed (Figure 4e ). This phenomena is consistent with another NHP study with an ADCC-enhanced antibody, 31 and it is speculated that the interaction of NK cells with susceptible target cells triggers NK-cell activation and cell death and/or margination and trafficking from the circulation. 32, 33 The numbers of NK cells in the PB began to recover 7 days post dose, independent of the return of basophils and pDCs. Importantly, in a separate NHP study where animals were administered CSL362 at a dose of up to 30 mg/kg, no effects on neutrophil, monocyte and total lymphocyte counts were observed (Supplementary Figure 3) , indicating that CSL362 is not affecting these mature lineages or progenitors in the BM.
These data demonstrated the efficacy of CSL362 in vivo, and highlight the use of PB basophil and pDC populations as biomarkers for monitoring CSL362 activity.
CSL362 mediates autologous depletion of AML cells ex vivo
The data presented thus far highlight the importance of NK-cell number and function in the mechanism of action of CSL362. To evaluate the function of NK cells in AML patients, depletion assays were established using blasts that were stored frozen at diagnosis as targets, and PBMC from the patients following induction and consolidation as effectors. The samples were incubated for 24 h with and without CSL362, and the remaining AML cells were quantitated by flow cytometry. CSL362-treated samples showed greater AML-cell depletion than the CSL360-treated samples. In the example shown (Figures 5a and b) , basophils were also monitored and showed a concomitant decrease upon CSL362 treatment. Importantly, in 5/7 samples tested, good levels of depletion were observed with CSL362 (Figure 5c ), despite low E:T ratios in some cases (Wilcoxon test, Po0.05). In 2/7 samples tested, low levels of depletion were observed. In one of these samples, the effector PBMCs were taken at a time when the patient had relapsed and the E:T ratio was o1, which may account for the low activity. These data support the premise that CSL362 is able to activate NK cells in AML patients in remission, and that AML blasts are susceptible to ADCC lysis by their own NK cells in the presence of CSL362.
DISCUSSION
The biological and molecular heterogeneity of AML and its increased prevalence in the elderly have proved problematic in developing safe and effective targeted therapies for this disease. Although many patients achieve complete remission following standard chemotherapy, the majority eventually relapse. Consequently, there is an unmet need for a safe, tolerable therapy to maintain AML remission, especially for patients at high risk of relapse. 34 An effective agent should target and specifically kill both leukemia cells and residual LSCs that are typically chemoresistant and capable of reinitiating the disease.
In the last few years, several cell-surface targets that are preferentially expressed by AML cells and LSCs have been À LSC by healthy donor NK cells at an E:T ratio of 10:1. Cells were incubated in the presence of increasing concentrations of CSL362 or a non-ADCCenhanced anti-CD123 mAb (CSL360) for 4 h at 37 1C. Cell lysis was ascertained by detection of LDH in the culture supernatant. Specific lysis was determined by normalizing the data to maximal (detergent) and minimal (NK cells alone) lysis. The highest specific lysis observed,which was routinely observed at concentrations above 0.1 mg/ml has been shown. NK cells from different donors were used in each experiment. identified including CD44, CLL-1, TIM-3, CD47 and CD96. 35 We and others have shown that CD123 is highly expressed on both the blast and LSC populations compared with normal hematopoietic stem cells. 13, 15, 36 This difference in expression coupled with the observation that CD123 is overexpressed in most AML cells irrespective of subgroup 13 suggests that targeting this molecule could be of wide benefit.
A number of approaches targeting CD123 are currently being investigated, including a diphtheria toxin-IL-3 fusion protein (DT 388 IL-3 /SL-401), 37, 38 T cells modified to express chimeric antigen receptors 39 and both bi-specific and tri-specific antibody fragments. 40, 41 Previously, we had evaluated the safety and tolerability of CSL360, a neutralizing chimeric anti-CD123 antibody, in a phase 1 study in relapsed/refractory AML patients. 16 Sustained saturation of CD123 on both PB and BM blasts associated with inhibition of IL-3 responsiveness of AML cells ex vivo was observed at doses X3 mg/kg. However, blockade of IL-3 signaling alone was insufficient to significantly impact disease in the majority of patients enrolled. Nevertheless, the saturation of CD123 in vivo by CSL360 together with our finding of a role for innate immunity in 7G3 eliminating LSC in a mouse model of AML 15 encouraged us to harness these properties and, in particular, optimize Fc receptor binding.
We have subsequently developed a second-generation anti-CD123 antibody, CSL362, which has been humanized and Fc-engineered to have over 100-fold increased affinity for CD16. This increased binding resulted in potent ADCC against CD123-expressing cell lines, primary AML samples and purified LSCs. The evaluation of neutrophils, monocytes, macrophages and NK cells in ADCC assays revealed that the major effector cells responsible for CSL362-mediated cytotoxicity were NK cells. A correlation between the level of lysis and CD123 expression was observed in cell lines that were genetically modified to express different levels of the target, an observation similar to previous studies, which have shown that although target expression is not as critical for ADCC compared with complement-mediated cytotoxicity, it does affect maximal lysis. 20, 22, 42 Although it is difficult to extrapolate these observations to primary cells owing to intrinsic differences between leukemias, it is important to note that CSL362-mediated ADCC was observed in all primary AML samples tested.
In AML xenograft models, we were able to demonstrate a clear effect of CSL362 in vivo. Despite the limitations of these models due to the immune-compromised nature of the animals and the structural differences between mouse and human Fc receptors, CSL362 was highly effective and more powerful than CSL360 at reducing leukemia cell growth. Significantly, in an in vivo model closer to man, administration of CSL362 to cynomolgus monkeys resulted in the rapid depletion of basophils and pDCs, two cell types that express high levels of CD123. This is an important demonstration of the depleting actions of CSL362 in vivo and has the added advantage of revealing two cellular biomarkers of antibody action.
As NK-cell numbers and function may be impaired in patients with relapsed disease and post-induction and consolidation therapies, 43 it was important to examine whether autologous NK cells from AML patients were able to elicit CSL362-mediated ADCC. Our data demonstrate that although the numbers of CD56 dim /CD16 þ NK cells in patients in remission may be low, they are still functionally capable of killing autologous blasts ex vivo in the presence of CSL362. Indeed, numerous reports have documented that NK cells are the first lymphocytes to recover 44 with numbers back to those observed in preconsolidation by 4 weeks post treatment. 45 Although AML can evade NK-cell cytotoxicity by downregulating ligands for the activating receptors on NK cells 46 (for example, NKG2D-L), it is important to note that cytotoxicity triggered by ADCC is dependent solely on activation of CD16; no priming or second trigger event is required and this activation is independent of inhibitory signals. 47 Furthermore, it has been shown that the level of CD16 expression on NK cells in AML patients is comparable to that of healthy donors, 48 suggesting that although the overall number of NK cells may be reduced in AML patients, sufficient numbers with full activation capacity remain to act on CSL362-coated cells.
The ability of CSL362 to mediate ADCC of leukemic cells by NK cells is an important finding that may be extended from an autologous to adoptive transfer settings. For example, in recent experiments, CSL362 has shown efficacy in preclinical AML xenograft models employing adoptive transfer of human NK cells following chemotherapy (Lee et al., submitted) . These data highlight the potential to use CSL362 in treatment strategies that aim to improve immune cell function such as post-stem cell transplant to direct NK-cell-mediated graft versus leukemia response or in combination with donor NK infusions or agents that are able to stimulate NK-cell expansion and activity.
These results strongly support the clinical development of CSL362 for the treatment of AML in patients with adequate NK-cell function. A phase 1 study of CSL362 in patients with CD123
þ AML in remission is on-going (Clinical Trials.gov identifier: NCT01632852).
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